Alchemab Therapeutics: Venture Capital Funding History
Alchemab Therapeutics
To add a bio or update company history, please click update information.
News from Alchemab Therapeutics
Alchemab Therapeutics
9 Jul 2026
Alchemab Therapeutics secures £25m Series A extension from British Business Bank to scale antibody drug discovery pipeline for hard-to-treat diseases
Alchemab Therapeutics is a clinical-stage biotechnology company that uncovers protective antibodies from disease-resilient individuals to discover and develop novel therapeutics. Its Resiliome platform combines a large human antibody database with AI-derived algorithms and lab validation to identify antibodies that protect against hard-to-treat diseases.
Alchemab Therapeutics
9 Sept 2025
Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.
Alchemab Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £49m
- alchemab.com
- Update Information
More venture news
- 23 Sept 2026
Basecamp ResearchBasecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Series CLife Sciences - 18 Sept 2026
Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences - 16 Sept 2026
Eterna RegenerativesEterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences
